151 related articles for article (PubMed ID: 16896007)
1. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.
Michael M; Thompson M; Hicks RJ; Mitchell PL; Ellis A; Milner AD; Di Iulio J; Scott AM; Gurtler V; Hoskins JM; Clarke SJ; Tebbut NC; Foo K; Jefford M; Zalcberg JR
J Clin Oncol; 2006 Sep; 24(26):4228-35. PubMed ID: 16896007
[TBL] [Abstract][Full Text] [Related]
2. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.
Wong M; Evans S; Rivory LP; Hoskins JM; Mann GJ; Farlow D; Clarke CL; Balleine RL; Gurney H
Clin Pharmacol Ther; 2005 Jan; 77(1):33-42. PubMed ID: 15637529
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
[TBL] [Abstract][Full Text] [Related]
4. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
5. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.
Kroetz DL
J Clin Oncol; 2006 Sep; 24(26):4225-7. PubMed ID: 16895999
[No Abstract] [Full Text] [Related]
6. Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.
Liu Z; Martin JH; Liauw W; McLachlan SA; Link E; Matera A; Thompson M; Jefford M; Hicks RJ; Cullinane C; Hatzimihalis A; Campbell I; Crowley S; Beale PJ; Karapetis CS; Price T; Burge ME; Michael M
Eur J Clin Pharmacol; 2022 Jan; 78(1):53-64. PubMed ID: 34480602
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
8. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
[TBL] [Abstract][Full Text] [Related]
9. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
11. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
12. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
[TBL] [Abstract][Full Text] [Related]
13. Old tracer for a new purpose: potential role for 99mTc-2-Methoxyisobutylisonitrile (99mTc-MIBI) in renal transplant care.
Dizdarevic S; Aplin M; Newport MJ; Ryan N; Holt S; Goubet S; Goldberg L; Miles KA; Peters AM
Nucl Med Commun; 2014 Oct; 35(10):1058-66. PubMed ID: 25025147
[TBL] [Abstract][Full Text] [Related]
14. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
15. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
16. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study.
Michael M; Liauw W; McLachlan SA; Link E; Matera A; Thompson M; Jefford M; Hicks RJ; Cullinane C; Hatzimihalis A; Campbell IG; Rowley S; Beale PJ; Karapetis CS; Price T; Burge ME
Cancer Chemother Pharmacol; 2021 Jul; 88(1):39-52. PubMed ID: 33755789
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
19. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Innocenti F; Schilsky RL; Ramírez J; Janisch L; Undevia S; House LK; Das S; Wu K; Turcich M; Marsh R; Karrison T; Maitland ML; Salgia R; Ratain MJ
J Clin Oncol; 2014 Aug; 32(22):2328-34. PubMed ID: 24958824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
